US · Healthcare · Biotechnology
EPS came in at -0.91 against a street estimate of -0.77 — a miss of 18.2%.
Analysts rate Biohaven Ltd. a buy (12 buy, 4 hold, 1 sell out of 17) with an average price target of $21.27.
| Fund | Stake |
|---|---|
| HHG PLC | 11.61% |
| BlackRock Inc | 8.75% |
| Suvretta Capital Management, LLC | 6.81% |
| Stifel Financial Corp | 6.58% |
| Jupiter Topco LLC | 5.68% |
| Woodline Partners LP | 5.07% |
| State Street Corp | 4.60% |
| D. E. Shaw & Co LP | 2.77% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 BIOHAVEN LTD. (BHVN) - FORM 8-K SUMMARY HEADLINE NUMBERS • Company received FDA partial clinical hold on September 4, 2026 on BHV-7000 program • Ove | 2026-09-10 |
| Material agreement · Q3 2026 BIOHAVEN LTD. - FORM 8-K SUMMARY (August 26, 2026) HEADLINE NUMBERS • Upfront payment from SK Biopharmaceuticals (SKBP): $400 million total ($350 mi | 2026-08-26 |
| Quarterly report · Q2 2026 BIOHAVEN LTD. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $238.0 million in cash and equivalents as of June 30, 2026 (down from $230.0 | 2026-08-10 |
| Results announced · Q3 2026 BIOHAVEN LTD. – Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Net Loss Q2 2026: $137.3 million ($0.91 per share) vs. $198.1 million ($1.94 per share) | 2026-08-10 |
| Board / officer change · Q3 2026 BIOHAVEN LTD. FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Biohaven Ltd. is a pharmaceutical company incorporated in the British Virgin Islands | 2026-08-07 |
| Board / officer change · Q3 2026 BIOHAVEN LTD. (BHVN) - FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Leadership Transition: Chief Scientific Officer Bruce Car, Ph.D. transitioni | 2026-07-09 |
| Quarterly report · Q1 2026 BIOHAVEN LTD. (BHVN) - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $273.1 million in cash and equivalents as of March 31, 2026 (up from $ | 2026-05-04 |
| Proxy statement · Q2 2026 BIOHAVEN LTD. PROXY STATEMENT SUMMARY CEO COMPENSATION • Vlad Coric, M.D., Chairman and CEO total compensation: Document does not specify exact 2025 | 2026-03-13 |
Readable in the app.
| Announcement | Date |
|---|---|
| Exclusive regional licensing deal with $80 million upfront payment and potential milestone Biohaven licensed rights to its MoDE pan-IgG degrader portfolio—led by BHV-1300 and including BHV-1310 and BHV-1320—to Ono Pharmaceutical for Japan, South Korea, Taiwan and ASEAN countries. | 2026-10-15 |
| Exclusive worldwide license agreement for Kv7 platform with $400M upfront Biohaven Bioscience signed a major licensing deal with SK Biopharmaceuticals (SKBP) on August 26, 2026, to license its Kv7 ion channel platform technology, including the experimental drug op | 2026-08-26 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Biohaven Ltd. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.